Objective:

To determine the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and advanced liver fibrosis, as well as the associated factors in patients with type 2 diabetes mellitus (T2D).

Approach:

• Study Design: Cross-sectional study including 149 patients with T2D, conducted over 6 months in Endocrinology-Diabetology and Hepato-Gastroenterology departments.
• Screening Method: Screening for steatosis and liver fibrosis was performed using FibroScan.

Key Findings:

• 69.1% of participants met the criteria for MASLD [95% CI (61.7–76.5)].
• Advanced fibrosis could not be ruled out in 17.4% of patients [95% CI (11.7-24.5)], with 4% at high risk (≥12 kPa).
• High Body Mass Index was an independent predictor of MASLD (aOR = 1.25; 95% CI (1.13–1.38); p < 0.001).
• Total cholesterol was an independent predictor of MASLD (aOR = 1.69; 95% CI (1.15–2.48); p = 0.007).
• Higher platelet distribution width (PDW) was associated with nearly a threefold increase in the odds of advanced fibrosis (aOR = 2.78; 95% CI: 1.08–7.21; p = 0.035).
• Increasing GGT levels were significantly associated with advanced fibrosis (aOR = 1.12; 95% CI: 1.03–1.21; p = 0.006).

Interpretation:

The study found a significant prevalence of MASLD in patients with T2D and identified key risk factors for advanced liver fibrosis.

Limitations:

• The study was limited to a single center and may not be generalizable.
• Exclusion of patients with other liver diseases may affect the findings.

Conclusion:

The study emphasizes the importance of identifying at-risk patients for effective management of liver disease.